Primary Objective: To assess prevalence of Gaucher disease (GD) diagnosed in pediatric patients presenting with unexplained splenomegaly (SMG) after exclusion of first intention-diagnoses (e.g. portal hypertension, haematological malignancy, hemolytic anemia, infection) based on clinical examination and routine biological tests (full blood count, reticulocytes, liver tests, abdominal ultrasound, Coombs test and Epstein Barr virus serology). Secondary Objectives: * To describe the rate of each identified disease category and the rate of patients with no final diagnosis at the end of the study in pediatric patients with unexplained SMG after exclusion of first intention diagnoses * To describe the characteristics (clinical, lab, genetics) of all pediatric patients included in the study and to describe the characteristics subdivided by identified disease category and absence of final diagnosis at the end of the study
The planned duration of this study is 39 months, which includes 36 months of patient recruitment.
Study Type
OBSERVATIONAL
Enrollment
60
Investigational Site Number 2500036
Amiens, France
Investigational Site Number 2500014
Angers, France
Investigational Site Number 2500034
Argenteuil, France
Investigational Site Number 2500039
Bayonne, France
Investigational Site Number 2500015
Besançon, France
Investigational Site Number 2500003
Percentage of patients diagnosed with GD among enrolled patients
Diagnosis of GD based on deficient β-glucocerebrosidase activity in peripheral blood leukocytes or other nucleated cells, or genetic analysis.
Time frame: Up to 3 months after inclusion
Rate of each identified disease category at the end of the study among enrolled patients
Time frame: Up to 3 months after inclusion
Rate of patients with no final diagnosis at the end of the study among enrolled patients
Time frame: Up to 3 months after inclusion
Number of patients based on specific char. (clinical, lab, genetics)
Detailed characteristics of all patients included in the study (clinical, lab, genetics) will be evaluated
Time frame: Up to 3 months after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Bordeaux, France
Investigational Site Number 2500038
Brest, France
Investigational Site Number 2500026
Caen, France
Investigational Site Number 2500018
Chambéry, France
Investigational Site Number 2500009
Clermont-Ferrand, France
...and 30 more locations